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Summary  
We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic 
anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor 
(MUD) haemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients 
were grouped by transplant conditioning containing either ATG (n=1283), alemtuzumab 
(n=261) or no serotherapy (NS) (n=293). The risks of chronic GvHD were significantly 
reduced when ATG or alemtuzumab were compared to no serotherapy (p=0.021 and p=0.003, 
respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared to 
ATG (P=0.012) and no serotherapy (p < 0.001). By multivariate analysis, when compared to 
ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 
0.14-0.47; p<0.001) and chronic GVHD (HR 0.58; 95% CI 0.35 – 0.94; p=0.027). OS was 
significantly better in ATG and alemtuzumab patients compared with no serotherapy 
(p=0.010 and p=0.025). Our data shows inclusion of serotherapy in MSD and MUD HSCT 
for patients with SAA reduces chronic GVHD and provides a survival advantage over 
patients not receiving serotherapy.  Notably, alemtuzumab reduced the risk of acute and 
chronic GvHD compared to ATG and indicates that alemtuzumab might be the serotherapy of 
choice for MSD and MUD transplants for SAA.  
Key words 
Transplantation 
Severe aplastic anemia (SAA) 
Anti-thymocyte globulin (ATG) 
Alemtuzumab 
Graft vs host disease (GVHD)
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Introduction 
Haemopoietic stem cell transplantation (HSCT) from a matched sibling donor (MSD) is the 
treatment of choice for children and young adults with idiopathic severe aplastic anemia 
(SAA), with overall survival rates of 75-100% 
1-6
. Moreover, HSCT from matched unrelated 
donors (MUD) represent the best second-line treatment option for SAA patients failing initial 
immunosuppression irrespective of age (if <60) 
7,8
. However, current problems remain graft 
failure (4-14%), acute GvHD (11-18%) and chronic GvHD (30-40%) 
9,10
. Chronic GvHD 
significantly impairs both quality of life and overall survival following HSCT 
11
. Risk factors 
for development of chronic GvHD include prior acute GvHD, use of peripheral blood as a 
source of stem cells, the use of a female donor for male recipients, mismatched and unrelated 
donors and older patient age 
12
. The occurrence of GvHD following HSCT for SAA offers no 
advantage for the patient, since no benefit from the graft versus leukemia (GVL) effect is 
expected, as seen following HSCT for acute leukemia.  
Until recently it was unclear whether serotherapy should be included in the conditioning 
regimen to negate the risk of GvHD, without increasing the risk of graft failure, infection or 
compromising overall survival. Indeed, the only prospective randomized trial to date which 
attempted to address this issue, failed to show any survival benefit from the addition of Anti-
Thymocyte Globulin (ATG) in the conditioning regimen, possibly due to slow accrual of 
patients and the study being inadequately powered 
9
. This study also showed no difference in 
the incidence of acute and chronic GvHD rates between T cell replete and ATG containing 
regimens.  In contrast, a more recent EBMT study showed that serotherapy using ATG did 
significantly benefit overall survival for MSD and MUD HSCT performed for SAA 
13
. 
However, the optimal in vivo T cell depletion regimen is not known with current guidelines 
from EBMT and British Committee for Standards in Haematology (BCSH) suggesting either 
ATG or Alemtuzumab as possible options 
7,14
. Recent reports from the UK using 
alemtuzumab as serotherapy in the conditioning regimen in both MSD and MUD 
transplantation for SAA have shown remarkably low rates of chronic GvHD compared to 
historical series 
15,16
. However, previous attempts to determine the optimal serotherapy 
regimen in SAA have been hampered by small numbers 
2,9
  
In order to investigate the optimal serotherapy regimen for HSCT for idiopathic SAA and its 
impact on main transplant outcomes, we retrospectively analysed a large series of adults and 
children who underwent MSD and MUD HSCT with idiopathic SAA who were reported to 
European Bone Marrow Transplantation (EBMT) Society between 2000 and 2013 using the 
EBMT database. The goal of the study was to identify the serotherapy regimen with the 
lowest rate of GvHD, which is a surrogate of long-term morbidity and mortality after HSCT.A
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METHODS 
Patients 
As per EBMT procedures (www.ebmt.org), this retrospective study was approved by the 
Severe Aplastic Anemia Working Party (SAAWP) and utilized data submitted with patient 
consent from 285 centers reporting to the EBMT database via the EBMT software (Promise) 
in the period 2000-2013.  
Eligible patients were those with SAA who received a MSD or MUD SCT between 2000 and 
2013. No selection was done regarding the conditioning regimen. However, only those 
undergoing first allogeneic transplants were included. Patients receiving cord blood as a 
source of stem cells and mismatched donors with one difference at the antigenic and/or allelic 
level in HLA-A, -B, -C, -DRB1 were excluded.   
Patients with inherited bone marrow failure syndromes were not included. The diagnosis of 
SAA was made using established definitions 
17-19
. Donor matching was performed for HLA-
A, -B, -C, DRB1 and DQB1.  Patients received chemotherapy or TBI-based conditioning 
with either ATG or alemtuzumab as serotherapy or no serotherapy (NS) prior to 
transplantation. The source (horse or rabbit) and dosing schedule of ATG, and details of 
immunosuppression were not available for analysis.  
Study Endpoints 
The primary study endpoint was the risk of chronic GvHD. Any grade of GvHD from day 
100 was included. Secondary endpoints included overall survival, graft failure and acute 
GvHD (grades II-IV).  Event free survival (EFS) was defined as the absence of engraftment, 
graft loss, second transplant, malignancy following transplant, relapse and death. Diagnosis 
of acute of chronic GvHD was made by individual centres.      
Statistical analysis  
Comparisons of characteristics between treatment groups were made using the 𝜒2 test for 
categorical data and Mann-Whitney or Kruskal-Wallis test for continuous variables. Overall 
Survival was defined as the time from allogeneic transplantation to death from any cause, 
with patients still alive at their last follow up being censored. Event Free Survival was 
defined as the time from transplant until the first event among graft failure, graft loss, second 
transplant, second malignancy, relapse or death; cases still at risk were censored at their last 
follow up. Probabilities of OS and EFS were computed using Kaplan-Meier estimator and 
compared by the Log-Rank test. Chronic GvHD was analyzed in a competing risk 
framework, with any of the failures included in EFS considered as competing event, and 
performing a landmark analysis including only patients who survived event-free up to 100 
days after transplant. The cumulative incidence of chronic GvHD was calculated by the 
proper non-parametric estimator and comparisons were made using the Gray test. The same 
competing event were considered for the development of acute GvHD, restricting to the first 
100 days. Since several dates of onset were missing, the occurrence of acute GvHD was 
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analyzed comparing percentages of cases and of competing events occurred by the day 100 
between the three groups of treatment. Adjusted comparisons of endpoints between treatment 
groups considered the following factors: age at transplant (as continuous variable), donor 
type (MSD versus MUD), gender mismatch (Male patients-Female donor versus all other 
combinations), stem cells source (peripheral blood versus bone marrow) and conditioning 
regimen (with TBI versus without TBI). Adjusted effects on overall survival, event free 
survival and chronic GvHD incidence were estimated in terms of hazard ratios using the Cox 
model with a shared random center effect (“frailty model”) to take into account unmeasured 
confounders related to belonging to the same center. Modification of the effect of the 
conditioning treatment in subgroups was explored including interaction terms.  
Adjusted effects on the occurrence of acute GvHD were estimated in terms of Odds Ratios 
using multinomial logistic regression, results are reported in terms of the Odds Ratio (OR) of 
developing acute GvHD rather than being event-free at day 100: OR>1 indicates a risk factor 
for acute GvHD while OR<1 indicates a protective factor. All p-values shown are from two-
sided tests and the reported confidence intervals (CI) refer to 95% boundaries. A significance 
level 5% was considered for all tests, except that for interactions, were 10% was applied. 
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Results 
The characteristics of the patients and their transplantations are summarized in Table 1. A 
total of 1837 patients were eligible for analysis: 1283 patients received ATG, 261 patients 
received alemtuzumab and 293 patients received no serotherapy in their transplant 
conditioning. The median age was 21.7 years (range 0.3- 76.8). 1155 patients received 
transplants from a MSD and 682 from a MUD   
In the ATG and no serotherapy group the commonest conditioning regimen was 
cyclophosphamide alone, in contrast to the alemtuzumab group which more commonly 
received fludarabine/cyclophosphamide (65.5%). More patients received alemtuzumab in 
their conditioning regimen as part of a MUD transplant than a MSD transplant (73.9% vs 
26.1%). This finding was reversed in the ATG and no serotherapy group.  
Hematopoietic recovery 
In each of the three treatment groups, patients were categorized as having engrafted, or as 
having primary or secondary graft failure. Overall, 1617 of 1816 (89%) patients successfully 
engrafted. Failure to engraft (i.e. the sum of primary and secondary graft failure) was not 
significantly different between the ATG, alemtuzumab and no serotherapy groups:  11.3%, 
9.6% and 10.7% respectively (p=0.732).   
Acute and Chronic GvHD 
Observed rates of grade 2-4 acute GvHD in the ATG, alemtuzumab and no serotherapy group 
were 13.3%, 6.7% and 19.1% respectively (P<0.001). This difference in the observed rates of 
acute GvHD was significantly reduced in favor of alemtuzumab compared to ATG (P=0.012) 
and no serotherapy (p < 0.001). Other variables associated with a higher probability of 
developing acute GvHD included MUD transplant and use of peripheral blood (PB) as source 
of stem cells: adjusted OR were 2.79 (p<0.001) for MUD versus MSD transplantation and 
1.49 (p= 0.011) for PB versus BM source. By multivariate analysis, when compared to ATG, 
alemtuzumab was associated with a lower risk of acute GvHD (OR 0.262; 95% CI 0.14-0.47; 
p<0.001). Compared to ATG, receiving no serotherapy led to a higher probability of 
developing acute GVHD (OR 1.647; 95% CI 1.12-2.41; p=0.010), whereas the use of 
alemtuzumab significantly reduced the risk of acute GvHD compared to NS (OR 0.159; 95% 
CI 0.08-0.31, p=0.000).  
Figure 1 (a) shows the cumulative incidence (CI) of chronic GvHD.  One thousand, two 
hundred and thirteen patients (N=1213, 66%) were evaluable for analysis: fifteen percent of 
patients (N=283,) were not considered at risk of chronic GvHD as they did not reach day 100 
alive and event free. Missing information on chronic GvHD accounted for a further 341 
(19%) cases. The 5-year cumulative probability of chronic GvHD in ATG, alemtuzumab and 
no serotherapy groups were 22.0% (95% CI 19.0 -25.1), 16.9% (95% CI 10.9-22.8) and 
30.4% (95% CI 24.0- 36.8) respectively (p=0.006). The risks were significantly reduced 
when either ATG or alemtuzumab were compared to no serotherapy (p=0.021 and p=0.003), 
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respectively. Between the two serotherapies, the difference in favor of alemtuzumab was 
borderline (p=0.083). All factors previously identified as associated with chronic GvHD, 
(age, donor type, gender mismatch, source and conditioning regimen - TBI yes vs no) 
retained a significant association with chronic GvHD in multivariate analysis (Table 2). After 
adjustment for these other covariates, alemtuzumab was associated with a significantly lower 
rate of chronic GvHD in comparison to both no serotherapy transplants (HR 0.43; 95% CI 
0.25 – 0.76; p =0.004) and ATG transplants (HR 0.58; 95% CI 0.35-0.94; P=0.027). 
 
Overall survival 
The 5-year cumulative probability of OS in the ATG, alemtuzumab and no serotherapy 
groups was 80.2% (95% CI 77.7-82.7 %), 81.5% (95% CI 76.1-86.8%) and 72.5% (95% CI 
67.1-78.0%) respectively (p=0.021) (Figure 1, b). OS was significantly better in both ATG 
and alemtuzumab patients compared with no serotherapy (p=0.010 and p=0.025 
respectively).  However, comparison between ATG and alemtuzumab failed to reach 
significance (p=0.604).  Factors significantly associated with OS in multivariate analysis 
included age, donor source and type of serotherapy (Table 3). In multivariate analysis, 
alemtuzumab was associated with a significantly increased OS in comparison to no 
serotherapy transplants (HR 0.48; 95% CI 0.32-0.74, p=0.001) and a trend towards 
significance against ATG transplants (0.73; 95% CI 0.51-1.04, p=0.081). 
Event free survival 
There was no difference in the rates of EFS across the three groups: the cumulative 
probability of achieving 5-year event free survival was 71.8% in the ATG group (95% CI 
68.9-74.6), 73.2% in the alemtuzumab-treated group (95% CI 66.9-79.4) and 68.3% in the 
group that received no serotherapy (95% CI 62.6-74.0; p=0.393) (Figure 1, (c)).   
Causes of Death 
Causes of death are categorized in Table 4 (Supplementary material). In all treatment groups, 
infection was the most common cause of death and accounted for 30.7-47.6% of deaths. 
There was no significant difference between the causes of death across the different types of 
serotherapy (p=0.131).  
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Discussion 
The present study is the largest analysis to document transplant outcomes after in vivo T- cell 
depletion (alemtuzumab or ATG) for adults and children with idiopathic SAA compared with 
T-cell replete HSCT. Retrospective data suggests that ATG improves survival 
13
. However, 
the optimal strategy for in-vivo T-cell depletion is uncertain. This is of particular importance 
as GvHD remains the most unwanted complication after HSCT in AA; furthermore chronic 
GVHD is a major factor in reducing long term survival in SAA HSCT survivors 
20
. Thus 
measures which prevent chronic GVHD in SAA HSCT are urgently required. Our analysis 
indicates that patients with acquired SAA who receive T-cell depletion with either ATG or 
alemtuzumab as part of their HSCT conditioning, have significantly lower risks of acute and 
chronic GvHD, and a survival advantage when compared to patients receiving no 
serotherapy. The lower GvHD rates seen with in vivo T-cell repletion were not offset by 
higher graft failure or lower EFS. Crucially, alemtuzumab significantly reduced rates of acute 
GvHD compared to ATG. By multivariate analysis, alemtuzumab was associated with a 
significantly lower rate of chronic GvHD compared to ATG-based transplantation and 
receiving no serotherapy. Taken together, these data suggest that alemtuzumab should be the 
preferred agent of choice for serotherapy in MSD and MUD HSCT in SAA  
This reduction in GvHD is highly desirable in view of the associated morbidity and mortality 
for the patients, with an associated increase in their quality of life 
11,20
. There are impacts for 
health services as chronic and severe GvHD is associated with an increased hospital stay. Our 
study has some limitations. The choice of treatment strategy (including the schedule, and 
dose of in vivo T cell depletion), diagnosis and management of chronic GvHD was decided 
by individual centres. Nevertheless, this is the largest study to date examining outcomes 
following in vivo T-cell depletion with ATG, alemtuzumab and T cell replete HSCT in SAA. 
Furthermore, in order to counter the inherent biases, we performed controlled comparisons of 
T cell replete and deplete with known prognostic factors. We recognize our study period 
spans 13 years, but when year of transplant was considered both as a continuous variable and 
categorical (2000-2005 vs 2006-2013), there was no difference in each of the outcomes. Age 
at transplantation was highly significant for every endpoint by multivariate analysis, showing 
an average increase of risk by 2-3% for every additional year of age.  
These data are in agreement with those reported by other groups, consistent with similarly 
low rates of chronic GvHD with alemtuzumab-based regimens; and this is associated with 
stable mixed T-cell chimerism that persists on withdrawal of post graft immunosuppression 
15,16,20
. 
The superior outcomes for acute and chronic GvHD seen with alemtuzumab compared to 
ATG could potentially be explained by a greater T-cell depletion. Whereas historically this 
would have led to a greater incidence of infections due to delayed immune reconstitution, this 
may no longer be the case because of advances in supportive care. Infection was the most 
common cause of death, with a trend for more infections in patients receiving serotherapy vs 
no serotherapy. There is a concern that alemtuzumab may increase the risk of viral infections 
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given its marked T-cell depleting properties. However, this risk was not higher using 
alemtuzumab compared to ATG, and does not appear to be higher compared with historical 
data using no serotherapy 
12
. The persistence of recipient CD8+ T-effector cells post 
fludarabine, cyclophosphamide, and alemtuzumab (Campath-1H) (FCC) HSCT for SAA that 
explains the mixed T-cell chimerism, may confer a degree of anti-virus immunity, since the 
incidence of CMV disease was low in a UK single center study 
21
. 
The OS observed in this study is broadly in-line with outcomes seen over this time period 
(2000-2015). We propose the predominant reason for the OS being 10% higher than EFS is 
salvage with a second transplant if graft failure of relapse occur.  The GvHD/relapse free 
survival (GRFS) is becoming more frequently used to track transplant outcome 
22
. The use of 
this composite endpoint may be the most appropriate indicator to monitor transplant 
outcomes following HSCT for SAA and its use should be considered for future studies.   
A recent retrospective review of 833 patients receiving either Horse or Rabbit ATG following 
HSCT for SAA, concluded that rabbit ATG rather than horse ATG should be used for the 
HSCT conditioning regimens for SAA 
23
. This was based on higher rates of acute and chronic 
GvHD when using horse ATG compared to rabbit ATG. In our data set, the subtype of ATG 
preparation was not collected. However, we would suggest that in the interim until a 
comparison is performed between alemtuzumab and rabbit ATG, due to the superiority of 
alemtuzumab over ATG in this analysis, alemtuzumab is the preferred serotherapy of choice.  
Whilst a randomized prospective study would have been preferable our data has important 
implications for clinical practice. We have shown that inclusion of serotherapy in MSD and 
MUD HSCT for patients with SAA reduces acute and chronic GvHD, and provides a survival 
advantage over patients not receiving serotherapy. These findings confirm that in vivo T cell 
depletion should be used for MSD and MUD HSCT for SAA. Our data also suggest that 
alemtuzumab is the preferred serotherapy agent of choice for both MSD and MUD 
transplants for SAA.  
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ATG Alemtuzumab No serotherapy P-value
No of patients 1283 (69.8%) 261 (14.2) 293 (15.9%)
Sex, n (% of treatment group)
Male 717 (55.9%) 144 (52.2%) 142 (48.5%) 0.069
Female 566 (44.1%) 117 (44.8%) 151 (51.5%)
 Age at transplantation, y (% of treatment group)
<15 years 368 (28.7%) 79 (30.3%) 58 (19.8%) 0.003
≥15 years 915 (71.3%) 182 (69.7%) 235 (80.2%)
Transplant type, n (% of treatment group)
Matched sibling 852 (66.4%) 68 (26.1%) 235 (80.2%) <0.001
Matched unrelated 431 (33.6%) 193 (73.9%) 58 (19.8%)
Conditioning  regimen , n (% of treatment group)
Cyclophosphamide 673 (52.5%) 28 ( 10.7%) 159 (54.3%) <0.001
Fludarabine /Cyclophosphamide 259 (20.2%) 171 (65.5%) 59 (20.1%)
Other 143 (11.1%) 38 (14.6%) 27 (9.2%)
TBI - based 208 (16.2%) 24 (9.2%) 48 (16.4%)
Year serotherapy received (% within year group) 
2000-2005 289 (66.1%) 44 (10.1%) 104 (23.8%) <0.001
2006-2013 994 (71.0% 217 (15.5%) 189 (13.5%)
Source of stem cells (% of treatment group)
Bone marrow 912 (71.1%) 153 (58.6%) 174 (59.4%) <0.001
Periperal blood 371 (28.9% 108 (41.4%) 119 (40.6%)
Gender match between recipient and donor, n (% of treatment group)
Gender mismatch (male patient, female donor) 277 (21.6%) 40 (15.3%) 70 (23.9%) 0.034
Gender matched (any other combination) 1006 (78.4%) 221 (84.7%) 223 (76.1%)
Recipient-donor CMV status, n (% of treatment group)
Neg/Neg 294 (25.7%) 112 (45.7%) 53 (20.2%) <0.001
Neg/Pos 96 (8.4%) 23 (9.4%) 20 (7.6%)
Pos/Neg 266 (23.3%) 43 (17.6%) 41 (15.6%)
Pos/Pos 488 (42.7%) 67 (27.3%) 148 (56.5%)
Median follow- up in months (range) 34.0 (0.7-178.2) 30.9 (1.1-134.4) 47.9 (1.8- 167.0) <0.001  
 
 
 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
14 
 
 
Table 2 Multivariate analysis of chronic GvHD 
HR (95% CI, p-value) Chronic GVHD 
Alemtuzumab vs ATG 0.58 (0.35- 0.94, p=0.027) 
ATG vs no serotherapy 0.75 (0.53-1.07, p=0.108) 
Alemtuzumab vs no serotherapy 0.43 (0.25-0.76, p=0.004) 
Age 1.02 (1.01-1.03, p<0.001) 
Unrelated donor vs HLA identical sibling 2.01 (1.44-2.79, p<0.001) 
Gender mismatch* 1.59 (1.19-2.13, p=0.002) 
PBSC vs BMSC 1.93 (1.43-2.60, p<0.001) 
TBI vs No TBI 1.52 (1.05-2.21, p=0.027) 
HR Hazard Ratio, 95% confidence interval, p-value. Age, continuous, effect associated to 
+1 year of age.   *Gender mismatch=male patient & female donor vs other combinations 
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Table 3 Multivariate analysis on Overall Survival 
HR (95% CI, p-value) Overall survival 
Alemtuzumab vs ATG 0.73 (0.51-1.04, p=0.081) 
ATG vs no serotherapy 0.67 (0.50-0.88, p=0.005) 
Alemtuzumab vs no serotherapy 0.48 (0.32-0.74, p=0.001) 
Age 1.03 (1.02-1.04, p<0.001) 
Unrelated donor vs HLA identical sibling 1.84 (1.45-2.34, p<0.001) 
HR Hazard Ratio, 95% confidence interval, p-value.  
 
 
Table 4 Causes of death by serotherapy 
  ATG Alemtuzumab No serotherapy 
No of deaths (n=223) (n=42) (n=75) 
Rejection/graft failure 58 (26.0%) 8 (19%) 15 (20.0%) 
GvHD 27 (12.1%) 5 (11.9%) 17 (22.7%) 
Infection 95 (42.6%) 20 (47.6%) 23 (30.7%) 
Organ damage/failure 7 (3.1%) 1 (2.4%) 4 (5.3%) 
Other 36 (16.1%) 8 (19.0%) 16 (21.3%) 
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